Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-blinded Placebo-controlled Study of Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort
Conditions
Interventions
CYT107
Placebo
Locations
2
United States
Memorial sloan kettering
New York, New York, United States
MD Anderson cancer center
Houston, Texas, United States
Start Date
December 20, 2020
Primary Completion Date
June 30, 2022
Completion Date
June 30, 2022
Last Updated
April 11, 2024
NCT06631287
NCT05101213
NCT04565665
NCT06871293
NCT04978571
NCT06082518
Lead Sponsor
Revimmune
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions